approach toward N-acylated aminotriazoles is reported, enabling the compounds’ screening against FXIIa and thrombin. This approach afforded low-nanomolar FXIIa and thrombin inhibitors with no off-targeting of the other tested serine proteases. Selected compounds were shown to be covalent inhibitors of FXIIa and demonstrated anticoagulant properties in vitro, influencing the intrinsic blood coagulation
抗凝剂进展:报道了一种 N-酰化
氨基三唑的微量平行合成方法,使该化合物能够针对 FXIIa 和凝血酶进行筛选。这种方法提供了低纳摩尔浓度的 FXIIa 和凝血酶
抑制剂,且其他测试的
丝氨酸蛋白酶没有脱靶。选定的化合物被证明是 FXIIa 的共价
抑制剂,并在体外表现出抗凝血特性,影响内在的凝血途径。